GR expression is seen in about 60% of breast cancers and appears to be associated with ER expression with about 70% of ER-positive tumors expressing GR compared with only about 30% of ER-negative tumors [65] (Figure 2). This evidence concerns the gene NR3C1 and breast carcinoma.